- Home
- RFI vs PRQR Comparison
RFI vs PRQR Comparison
Compare RFI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- PRQR
- Stock Information
- Founded
- RFI 1992
- PRQR 2012
- Country
- RFI United States
- PRQR Netherlands
- Employees
- RFI N/A
- PRQR N/A
- Industry
- RFI Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- PRQR Health Care
- Exchange
- RFI Nasdaq
- PRQR Nasdaq
- Market Cap
- RFI 323.2M
- PRQR 179.1M
- IPO Year
- RFI N/A
- PRQR 2014
- Fundamental
- Price
- RFI $11.90
- PRQR $2.35
- Analyst Decision
- RFI
- PRQR Strong Buy
- Analyst Count
- RFI 0
- PRQR 8
- Target Price
- RFI N/A
- PRQR $8.88
- AVG Volume (30 Days)
- RFI 69.8K
- PRQR 357.1K
- Earning Date
- RFI 01-01-0001
- PRQR 08-07-2025
- Dividend Yield
- RFI 8.25%
- PRQR N/A
- EPS Growth
- RFI N/A
- PRQR N/A
- EPS
- RFI N/A
- PRQR N/A
- Revenue
- RFI N/A
- PRQR $21,212,711.00
- Revenue This Year
- RFI N/A
- PRQR N/A
- Revenue Next Year
- RFI N/A
- PRQR N/A
- P/E Ratio
- RFI N/A
- PRQR N/A
- Revenue Growth
- RFI N/A
- PRQR 85.91
- 52 Week Low
- RFI $9.62
- PRQR $1.07
- 52 Week High
- RFI $12.52
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- RFI 46.23
- PRQR 66.90
- Support Level
- RFI $11.85
- PRQR $2.10
- Resistance Level
- RFI $12.18
- PRQR $2.18
- Average True Range (ATR)
- RFI 0.13
- PRQR 0.13
- MACD
- RFI -0.02
- PRQR 0.01
- Stochastic Oscillator
- RFI 34.88
- PRQR 56.92
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.